Team announcement

Adlai Nortye Announces Formation of its New Scientific Advisory Board

Adlai Nortye Announces Formation of its New Scientific Advisory Board, Adlai Nortye Biopharma Co., Ltd.

HANGZHOU, China, March 7, 2021 /PRNewswire/ -- Adlai Nortye, a global clinical-stage biopharmaceutical company, today announced the formation of its new Scientific Advisory Board (SAB) comprised of five internationally renowned experts. The SAB includes Ronald M. Evans, PhD (Member of the US National Academy of Sciences, Professor at the Salk Institute and Director of the Salk's Gene Expression Laboratory), Tony Hunter, PhD (Member of the US National Academy of Sciences, Professor of Molecular and Cell Biology at the Salk Institute), Jason Pontin (Investor and former senior partner at Flagship Pioneering), Andrew Zhu, MD, PhD (Professor of Medicine at Harvard Medical School) and Wenle Xia, MD (former faculty member at Duke University).

Chaired by Dr. Ronald M. Evans, the inaugural members are leading experts in the areas of oncology, clinical science and life science investment. The SAB will guide and advise the Company as it advances its preclinical and clinical immuno-oncology programs to address unmet medical needs.

"We are excited and honored to have a prestigious and accomplished experts joining as inaugural members of our new Scientific Advisory Board," said Carsten Lu, President and Chief Executive Officer of Adlai Nortye. "Their expertise and insightful perspectives will provide excellent support for the advancement of Adlai Nortye's scientific programs to help patients live longer and live better."

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.